J Med Chem. 2019 Dec 12;62(23):10645-10663. doi: 10.1021/acs.jmedchem.9b00966. Epub 2019 Nov 26.
Overexpression of ABC transporters like P-glycoprotein (P-gp) has been correlated with resistances in cancer chemotherapy. Intensive efforts to identify P-gp inhibitors for use in combination therapy have not led to clinically approved inhibitors to date. Here, we describe computational approaches combined with structure-based design to improve the characteristics of a P-gp inhibitor previously identified by us. This hit compound represents a novel class of P-gp inhibitors that specifically targets and inhibits P-gp ATP hydrolysis while not being transported by the pump. We describe here a new program for virtual chemical synthesis and computational assessment, ChemGen, to produce hit compound variants with improved binding characteristics. The chemical syntheses of several variants, efficacy in reversing multidrug resistance in cell culture, and biochemical assessment of the inhibition mechanism are described. The usefulness of the computational predictions of binding characteristics of the inhibitor variants is discussed and compared to more traditional structure-based approaches.
ABC 转运蛋白(如 P-糖蛋白)的过度表达与癌症化疗中的耐药性有关。人们一直在努力寻找 P-糖蛋白抑制剂,以期将其用于联合治疗,但迄今为止尚未发现临床上可批准的抑制剂。在这里,我们描述了结合结构的计算方法基于设计来改进我们之前确定的 P-糖蛋白抑制剂的特性。该命中化合物代表了一类新型的 P-糖蛋白抑制剂,它专门针对并抑制 P-糖蛋白 ATP 水解,而不会被泵转运。我们在这里描述了一个新的虚拟化学合成和计算评估程序 ChemGen,用于生成具有改善结合特性的命中化合物变体。描述了几种变体的化学合成、在细胞培养中逆转多药耐药的功效以及对抑制机制的生化评估。讨论了抑制剂变体结合特性的计算预测的有用性,并将其与更传统的基于结构的方法进行了比较。